|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Enrolling by invitationPhase 1 Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors
This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.
100 Clinical Results associated with PendreaBio Inc.
0 Patents (Medical) associated with PendreaBio Inc.
100 Deals associated with PendreaBio Inc.
100 Translational Medicine associated with PendreaBio Inc.